Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho/Fibroblast Growth Factor 23 System.
作者信息
Bittmann Stefan, Moschuring-Alieva Elena, Luchter Elisabeth, Villalon Gloria
机构信息
Department of Pediatrics, Ped Mind Institute, Hindenburgring 4, D-48599 Gronau, Germany.
出版信息
J Clin Med Res. 2022 Oct;14(10):436-439. doi: 10.14740/jocmr4820. Epub 2022 Oct 28.
Abstract
摘要
相似文献
1
Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho/Fibroblast Growth Factor 23 System.
J Clin Med Res. 2022 Oct;14(10):436-439. doi: 10.14740/jocmr4820. Epub 2022 Oct 28.
2
Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
FASEB J. 2009 Nov;23(11):3702-11. doi: 10.1096/fj.08-123992. Epub 2009 Jul 7.
3
FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
J Cell Physiol. 2017 Mar;232(3):610-616. doi: 10.1002/jcp.25458. Epub 2016 Jun 30.
4
[Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].
Clin Calcium. 2010 Jun;20(6):896-903.
5
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
N Engl J Med. 2003 Apr 24;348(17):1656-63. doi: 10.1056/NEJMoa020881.
6
Targeted inhibition of Klotho binding to fibroblast growth factor 23 prevents hypophosphetemia.
J Mol Graph Model. 2017 Aug;75:9-19. doi: 10.1016/j.jmgm.2017.04.024. Epub 2017 Apr 27.
7
FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Med Hypotheses. 2014 Oct;83(4):482-7. doi: 10.1016/j.mehy.2014.08.005. Epub 2014 Aug 11.
8
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):407-12. doi: 10.1073/pnas.0902006107. Epub 2009 Dec 4.
9
FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Orphanet J Rare Dis. 2019 Feb 26;14(1):58. doi: 10.1186/s13023-019-1014-8.
10
Phosphate Dysregulation and Neurocognitive Sequelae.
Adv Exp Med Biol. 2022;1362:151-160. doi: 10.1007/978-3-030-91623-7_13.
本文引用的文献
1
A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia.
Sci Adv. 2021 Oct 29;7(44):eabj5018. doi: 10.1126/sciadv.abj5018. Epub 2021 Oct 27.
2
Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):813-824. doi: 10.1210/clinem/dgab729.
3
X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
Front Endocrinol (Lausanne). 2021 Aug 6;12:688309. doi: 10.3389/fendo.2021.688309. eCollection 2021.
4
Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real world setting.
Bone. 2021 Oct;151:116025. doi: 10.1016/j.bone.2021.116025. Epub 2021 May 28.
5
Burosumab for Pediatric X-Linked Hypophosphatemia.
Curr Osteoporos Rep. 2021 Jun;19(3):271-277. doi: 10.1007/s11914-021-00669-9. Epub 2021 May 10.
6
Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations.
Endocr Connect. 2020 Oct;9(10):1051-1056. doi: 10.1530/EC-20-0291.
7
Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting.
Eur J Endocrinol. 2020 Nov;183(5):497-504. doi: 10.1530/EJE-20-0275.
8
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Curr Opin Nephrol Hypertens. 2020 Sep;29(5):531-536. doi: 10.1097/MNH.0000000000000631.
9
The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study.
Orphanet J Rare Dis. 2020 Jun 30;15(1):172. doi: 10.1186/s13023-020-01434-4.
10
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children.
Front Endocrinol (Lausanne). 2020 May 28;11:338. doi: 10.3389/fendo.2020.00338. eCollection 2020.
Zotero 插件